Physician profile
Tabitha S Bond
NPI 1578734166
$9,219.40
in general payments reported to CMS, 2019-2025
37 companies · $1,402 in 2025
The $1,402 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,617 · 2022: $1,552 · 2023: $2,179 · 2024: $1,469 · 2025: $1,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,021 · Education: $28.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,021.05 |
| Education | $28.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,262.84 | 2021-2025 | Dovato, Cabenuva, Apretude |
| Abbvie INC. | $1,313.17 | 2021-2025 | |
| Glaxosmithkline, LLC. | $977.30 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $888.35 | 2021-2025 | Fasenra, Breztri, Airsupra |
| Novo Nordisk INC | $662.00 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $503.02 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Renalytix Ai, INC. | $372.04 | 2023-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Gilead Sciences, INC. | $369.29 | 2021-2025 | Yeztugo |
| Janssen Pharmaceuticals, INC | $301.05 | 2021-2025 | Spravato |
| Pfizer INC. | $295.58 | 2021-2025 | |
| Daiichi Sankyo INC. | $152.72 | 2022-2025 | Enhertu |
| Boston Scientific Corporation | $127.12 | 2022 | |
| Janssen Products, LP | $99.00 | 2022 | |
| Corcept Therapeutics | $81.38 | 2022-2025 | Korlym |
| Biohaven Pharmaceuticals, INC. | $76.01 | 2021 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Bond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.